Safety of fluoroquinolones in pediatric patients: Pharmacovigilance database analysis
Abstract
Background Due to the rising prevalence of resistant bacteria, there is a growing tendency to prescribe fluoroquinolones (FQs) to pediatric patients. Real world safety parameters of FQs in children may be studied using data of national pharmacovigilance databases. The aim of our study was to estimate the structure of adverse drug reactions (ADR) associated with FQs in pediatric patients. Materials and methods retrospective study of spontaneous reports registered in Russian National Pharmacovigilance database–Automatized Information System “Pharmacovigilance” for the period: 1 April 2019–31 January 2024. Results Total number of pediatric SRs was 280 (19.2%). Mean age was 12.1 ± 5.9 years (min – 1 day, max – 18 years), and adolescents were the most involved age group (n = 176, 62.9%). Mean time to ADR onset was 13.9 + 41.0 (min = 0, max = 303) days. Leading FQs were levofloxacin (49.6%, n = 139), ciprofloxacin (31.1%, n = 87), and moxifloxacin (15%, n = 42). Top-5 SOCs included “Immune disorders” (18.9%), “Gastrointestinal disorders” (15.0%), “Skin and subcutaneous tissue disorders” (14.7%), “General disorders and administration site conditions” (11.7%), and “Investigations” (7.6%). Top-5 PTs were urticaria, diarrhea, rash, arthralgia, and pruritus. Conclusions Levofloxacin, ciprofloxacin, and moxifloxacin were the primary FQs linked to ADRs in the pediatric population. Most prevalent were allergic reactions. Children receiving FQs should be closely monitored from the start of…
Read the paper
Related studies
- Synthesis, In Vitro and In Silico Molecular Docking Studies of Novel Phthalimide–Pyrimidine Hybrid Analogues to Thalidomide as Potent Antitubercular Agents
- Exploring the inhibitory performance of expired moxifloxacin and norfloxacin on copper corrosion in saline environment
- Molecular investigation of antimicrobial peptides against Helicobacter pylori proteins using a peptide-protein docking approach
- Screening of novel narrow-spectrum benzofuroxan derivatives for the treatment of multidrug-resistant tuberculosis through in silico, in vitro, and in vivo approaches
- Synthesis, Characterization, Anticancer, Antioxidant, and In Silico Evaluation of Semicarbazides and Thiosemicarbazides
- Fast and accurate prediction of drug induced proarrhythmic risk with sex specific cardiac emulators
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.